Is it time to test biguanide metformin in the treatment of melanoma?

Pigment Cell and Melanoma Research

Volumn 28, Issue 1, 2015, Pages 8-20

  Cerezo, Michael ^a,b   Tomic, Tijana ^a,b   Ballotti, Robert ^a,b,c   Rocchi, Stéphane ^a,b,c  

^a CENTRE MÉDITERRANÉEN DE MÉDECINE MOLÉCULAIRE C3M   (France)

^b UNIVERSITÉ CÔTE D'AZUR   (France)

^c CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

Author keywords

AMP activated protein kinase; Apoptosis; Cancers; Melanoma; Metformin

Indexed keywords

ADENYLATE KINASE; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; METFORMIN; PROTEIN KINASE LKB1; ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER CHEMOTHERAPY; CELL CYCLE ARREST; DRUG MECHANISM; DRUG PROTEIN BINDING; ENZYME ACTIVATION; HUMAN; MELANOMA; SIGNAL TRANSDUCTION; BIOLOGICAL MODEL; DRUG EFFECTS; SKIN NEOPLASMS;

MAMMALIA;

ANTINEOPLASTIC AGENTS; HUMANS; MELANOMA; METFORMIN; MODELS, BIOLOGICAL; SIGNAL TRANSDUCTION; SKIN NEOPLASMS;

EID: 84919860686     PISSN: 17551471     EISSN: 1755148X     Source Type: Journal    
DOI: 10.1111/pcmr.12267     Document Type: Article

References (116)

1. Agarwal, K.C., Parks, R.E. Jr, Widness, J.A., and Schwartz, R. (1985). Nonenzymatic glycosylation of erythrocytic proteins in normal and diabetic subjects. Enzymes of nucleoside and nucleotide metabolism. Diabetes 34, 251-255.
2. Algire, C., Zakikhani, M., Blouin, M.J., Shuai, J.H., and Pollak, M. (2008). Metformin attenuates the stimulatory effect of a high-energy diet on in vivo LLC1 carcinoma growth. Endocr. Relat. Cancer 15, 833-839.
3. Algire, C., Amrein, L., Bazile, M., David, S., Zakikhani, M., and Pollak, M. (2011). Diet and tumor LKB1 expression interact to determine sensitivity to anti-neoplastic effects of metformin in vivo. Oncogene 30, 1174-1182.
4. Alimova, I.N., Liu, B., Fan, Z., Edgerton, S.M., Dillon, T., Lind, S.E., and Thor, A.D. (2009). Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle 8, 909-915.
5. Aljada, A., and Mousa, S.A. (2012). Metformin and neoplasia: implications and indications. Pharmacol. Ther. 133, 108-115.
6. Anisimov, V.N., Egormin, P.A., Piskunova, T.S., Popovich, I.G., Tyndyk, M.L., Yurova, M.N., Zabezhinski, M.A., Anikin, I.V., Karkach, A.S., and Romanyukha, A.A. (2010). Metformin extends life span of HER-2/neu transgenic mice and in combination with melatonin inhibits growth of transplantable tumors in vivo. Cell Cycle 9, 188-197.
7. Aplin, A.E., Kaplan, F.M., and Shao, Y. (2011). Mechanisms of resistance to RAF inhibitors in melanoma. J. Invest. Dermatol. 131, 1817-1820.
8. Bae, E.J., Cho, M.J., and Kim, S.G. (2007). Metformin prevents an adaptive increase in GSH and induces apoptosis under the conditions of GSH deficiency in H4IIE cells. J. Toxicol. Environ. Health A 70, 1371-1380.
9. Barnett, A.H. (2010). Avoiding hypoglycaemia while achieving good glycaemic control in type 2 diabetes through optimal use of oral agent therapy. Curr. Med. Res. Opin. 26, 1333-1342.
10. Ben Sahra, I., Laurent, K., Loubat, A., Giorgetti-Peraldi, S., Colosetti, P., Auberger, P., Tanti, J.F., Le Marchand-Brustel, Y., and Bost, F. (2008). The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 27, 3576-3586.
11. Ben Sahra, I., Laurent, K., Giuliano, S. et al. (2010). Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells. Cancer Res. 70, 2465-2475.
12. Ben Sahra, I., Regazzetti, C., Robert, G., Laurent, K., Le Marchand-Brustel, Y., Auberger, P., Tanti, J.F., Giorgetti-Peraldi, S., and Bost, F. (2011). Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. Cancer Res. 71, 4366-4372.
13. Bodmer, M., Meier, C., Krahenbuhl, S., Jick, S.S., and Meier, C.R. (2010). Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care 33, 1304-1308.
14. Boudeau, J., Scott, J.W., Resta, N., Deak, M., Kieloch, A., Komander, D., Hardie, D.G., Prescott, A.R., Van Aalten, D.M., and Alessi, D.R. (2004). Analysis of the LKB1-STRAD-MO25 complex. J. Cell Sci. 117, 6365-6375.
15. Bowker, S.L., Majumdar, S.R., Veugelers, P., and Johnson, J.A. (2006). Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 29, 254-258.
16. Buzzai, M., Jones, R.G., Amaravadi, R.K., Lum, J.J., Deberardinis, R.J., Zhao, F., Viollet, B., and Thompson, C.B. (2007). Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res. 67, 6745-6752.
17. Cantrell, L.A., Zhou, C., Mendivil, A., Malloy, K.M., Gehrig, P.A., and Bae-Jump, V.L. (2010). Metformin is a potent inhibitor of endometrial cancer cell proliferation-implications for a novel treatment strategy. Gynecol. Oncol. 116, 92-98.
18. Cerezo, M., Tichet, M., Abbe, P. et al. (2013). Metformin blocks melanoma invasion and metastasis development in a AMPK/p53-dependent manner. Mol. Cancer Ther. 12, 1605-1615.
19. Currie, C.J., Poole, C.D., and Gale, E.A. (2009). The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 52, 1766-1777.
20. Destefano, M.A., and Jacinto, E. (2013). Regulation of insulin receptor substrate-1 by mTORC2 (mammalian target of rapamycin complex 2). Biochem. Soc. Trans. 41, 896-901.
21. Dowling, R.J., Zakikhani, M., Fantus, I.G., Pollak, M., and Sonenberg, N. (2007). Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res. 67, 10804-10812.
22. Dowling, R.J., Goodwin, P.J., and Stambolic, V. (2011). Understanding the benefit of metformin use in cancer treatment. BMC Med. 9, 33.
23. El-Mir, M.Y., Nogueira, V., Fontaine, E., Averet, N., Rigoulet, M., and Leverve, X. (2000). Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J. Biol. Chem. 275, 223-228.
24. Eskelinen, E.L. (2008). New insights into the mechanisms of macroautophagy in mammalian cells. Int. Rev. Cell Mol. Biol. 266, 207-247.
25. Evans, J.M., Donnelly, L.A., Emslie-Smith, A.M., Alessi, D.R., and Morris, A.D. (2005). Metformin and reduced risk of cancer in diabetic patients. BMJ 330, 1304-1305.
26. Foretz, M., Hebrard, S., Leclerc, J., Zarrinpashneh, E., Soty, M., Mithieux, G., Sakamoto, K., Andreelli, F., and Viollet, B. (2010). Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J. Clin. Invest. 120, 2355-2369.
27. Frasca, F., Pandini, G., Sciacca, L., Pezzino, V., Squatrito, S., Belfiore, A., and Vigneri, R. (2008). The role of insulin receptors and IGF-I receptors in cancer and other diseases. Arch. Physiol. Biochem. 114, 23-37.
28. Giovannucci, E., Harlan, D.M., Archer, M.C., Bergenstal, R.M., Gapstur, S.M., Habel, L.A., Pollak, M., Regensteiner, J.G., and Yee, D. (2010). Diabetes and cancer: a consensus report. CA Cancer J. Clin. 60, 207-221.
29. Goodwin, P.J., Pritchard, K.I., Ennis, M., Clemons, M., Graham, M., and Fantus, I.G. (2008). Insulin-lowering effects of metformin in women with early breast cancer. Clin. Breast Cancer 8, 501-505.
30. Gotlieb, W.H., Saumet, J., Beauchamp, M.C., Gu, J., Lau, S., Pollak, M.N., and Bruchim, I. (2008). In vitro metformin anti-neoplastic activity in epithelial ovarian cancer. Gynecol. Oncol. 110, 246-250.
31. Green, D.R. (1998). Apoptosis. Death deceiver. Nature 396, 629-630.
32. Guertin, D.A., and Sabatini, D.M. (2007). Defining the role of mTOR in cancer. Cancer Cell 12, 9-22.
33. Gwinn, D.M., Shackelford, D.B., Egan, D.F., Mihaylova, M.M., Mery, A., Vasquez, D.S., Turk, B.E., and Shaw, R.J. (2008). AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol. Cell 30, 214-226.
34. Hardie, D.G. (2008). AMPK: a key regulator of energy balance in the single cell and the whole organism. Int. J. Obes. (Lond) 32(Suppl 4), S7-S12.
35. Hardie, D.G., and Sakamoto, K. (2006). AMPK: a key sensor of fuel and energy status in skeletal muscle. Physiology (Bethesda) 21, 48-60.
36. Hemminki, A., Markie, D., Tomlinson, I. et al. (1998). A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. Nature 391, 184-187.
37. Hirsch, H.A., Iliopoulos, D., and Struhl, K. (2013). Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth. Proc. Natl Acad. Sci. USA 110, 972-977.
38. Hoek, K.S., and Goding, C.R. (2010). Cancer stem cells versus phenotype-switching in melanoma. Pigment Cell Melanoma Res. 23, 746-759.
39. Horman, S., Browne, G., Krause, U., Patel, J., Vertommen, D., Bertrand, L., Lavoinne, A., Hue, L., Proud, C., and Rider, M. (2002). Activation of AMP-activated protein kinase leads to the phosphorylation of elongation factor 2 and an inhibition of protein synthesis. Curr. Biol. 12, 1419-1423.
40. Hosono, K., Endo, H., Takahashi, H. et al. (2010). Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial. Cancer Prev. Res. (Phila) 3, 1077-1083.
41. Huang, X., Wullschleger, S., Shpiro, N., Mcguire, V.A., Sakamoto, K., Woods, Y.L., Mcburnie, W., Fleming, S., and Alessi, D.R. (2008). Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice. Biochem. J. 412, 211-221.
42. Inoki, K., Ouyang, H., Zhu, T. et al. (2006). TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell 126, 955-968.
43. Isakovic, A., Harhaji, L., Stevanovic, D., Markovic, Z., Sumarac-Dumanovic, M., Starcevic, V., Micic, D., and Trajkovic, V. (2007). Dual antiglioma action of metformin: cell cycle arrest and mitochondria-dependent apoptosis. Cell. Mol. Life Sci. 64, 1290-1302.
44. Jager, S., Bucci, C., Tanida, I., Ueno, T., Kominami, E., Saftig, P., and Eskelinen, E.L. (2004). Role for Rab7 in maturation of late autophagic vacuoles. J. Cell Sci. 117, 4837-4848.
45. Janjetovic, K., Harhaji-Trajkovic, L., Misirkic-Marjanovic, M., Vucicevic, L., Stevanovic, D., Zogovic, N., Sumarac-Dumanovic, M., Micic, D., and Trajkovic, V. (2011). In vitro and in vivo anti-melanoma action of metformin. Eur. J. Pharmacol. 668, 373-382.
46. Jones, R.G., Plas, D.R., Kubek, S., Buzzai, M., Mu, J., Xu, Y., Birnbaum, M.J., and Thompson, C.B. (2005). AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol. Cell 18, 283-293.
47. Kabeya, Y., Mizushima, N., Ueno, T., Yamamoto, A., Kirisako, T., Noda, T., Kominami, E., Ohsumi, Y., and Yoshimori, T. (2000). LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J. 19, 5720-5728.
48. Kalender, A., Selvaraj, A., Kim, S.Y. et al. (2010). Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metab. 11, 390-401.
49. Kefas, B.A., Cai, Y., Kerckhofs, K., Ling, Z., Martens, G., Heimberg, H., Pipeleers, D., and Van De Casteele, M. (2004). Metformin-induced stimulation of AMP-activated protein kinase in beta-cells impairs their glucose responsiveness and can lead to apoptosis. Biochem. Pharmacol. 68, 409-416.
50. Kimura, N., Tokunaga, C., Dalal, S., Richardson, C., Yoshino, K., Hara, K., Kemp, B.E., Witters, L.A., Mimura, O., and Yonezawa, K. (2003). A possible linkage between AMP-activated protein kinase (AMPK) and mammalian target of rapamycin (mTOR) signalling pathway. Genes Cells 8, 65-79.
51. Klionsky, D.J. (2005). Autophagy. Curr. Biol. 15, R282-R283.
52. Kroemer, G., and Pouyssegur, J. (2008). Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 13, 472-482.
53. Kudo, N., Gillespie, J.G., Kung, L., Witters, L.A., Schulz, R., Clanachan, A.S., and Lopaschuk, G.D. (1996). Characterization of 5′AMP-activated protein kinase activity in the heart and its role in inhibiting acetyl-CoA carboxylase during reperfusion following ischemia. Biochim. Biophys. Acta 1301, 67-75.
54. Kuhajda, F.P. (2000). Fatty-acid synthase and human cancer: new perspectives on its role in tumor biology. Nutrition 16, 202-208.
55. Kuma, A., Hatano, M., Matsui, M., Yamamoto, A., Nakaya, H., Yoshimori, T., Ohsumi, Y., Tokuhisa, T., and Mizushima, N. (2004). The role of autophagy during the early neonatal starvation period. Nature 432, 1032-1036.
56. Kundu, M., Lindsten, T., Yang, C.Y., Wu, J., Zhao, F., Zhang, J., Selak, M.A., Ney, P.A., and Thompson, C.B. (2008). Ulk1 plays a critical role in the autophagic clearance of mitochondria and ribosomes during reticulocyte maturation. Blood 112, 1493-1502.
57. Kwong, S.C., and Brubacher, J. (1998). Phenformin and lactic acidosis: a case report and review. J. Emerg. Med. 16, 881-886.
58. Lalau, J.D., and Race, J.M. (1999). Lactic acidosis in metformin therapy. Drugs 58(Suppl 1), 55-60; discussion 75-82.
59. Levine, B., and Klionsky, D.J. (2004). Development by self-digestion: molecular mechanisms and biological functions of autophagy. Dev. Cell 6, 463-477.
60. Liang, J., Shao, S.H., Xu, Z.X. et al. (2007). The energy sensing LKB1-AMPK pathway regulates p27(kip1) phosphorylation mediating the decision to enter autophagy or apoptosis. Nat. Cell Biol. 9, 218-224.
61. Libby, G., Donnelly, L.A., Donnan, P.T., Alessi, D.R., Morris, A.D., and Evans, J.M. (2009). New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 32, 1620-1625.
62. Lizcano, J.M., Goransson, O., Toth, R. et al. (2004). LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1. EMBO J. 23, 833-843.
63. Lub, R., Denig, P., Van Den Berg, P.B., Hoogenberg, K., Berg, De.Jong.-Van.Den., and L. T ., (2006). The impact of new insights and revised practice guidelines on prescribing drugs in the treatment of Type 2 diabetes mellitus. Br. J. Clin. Pharmacol. 62, 660-665.
64. Luo, Z., Zang, M., and Guo, W. (2010). AMPK as a metabolic tumor suppressor: control of metabolism and cell growth. Future Oncol. 6, 457-470.
65. Maiuri, M.C., Tasdemir, E., Criollo, A., Morselli, E., Vicencio, J.M., Carnuccio, R., and Kroemer, G. (2009). Control of autophagy by oncogenes and tumor suppressor genes. Cell Death Differ. 16, 87-93.
66. Malki, A., and Youssef, A. (2011). Antidiabetic drug metformin induces apoptosis in human MCF breast cancer via targeting ERK signaling. Oncol. Res. 19, 275-285.
67. Martin, M.J., Hayward, R., Viros, A., and Marais, R. (2012). Metformin accelerates the growth of BRAF V600E-driven melanoma by upregulating VEGF-A. Cancer Discov. 2, 344-355.
68. Mehrpour, M., Esclatine, A., Beau, I., and Codogno, P. (2010). Overview of macroautophagy regulation in mammalian cells. Cell Res. 20, 748-762.
69. Meijer, A.J., and Codogno, P. (2009). Autophagy: regulation and role in disease. Crit. Rev. Clin. Lab. Sci. 46, 210-240.
70. Memmott, R.M., Mercado, J.R., Maier, C.R., Kawabata, S., Fox, S.D., and Dennis, P.A. (2010). Metformin prevents tobacco carcinogen-induced lung tumorigenesis. Cancer Prev. Res. (Phila) 3, 1066-1076.
71. Mizushima, N., Noda, T., Yoshimori, T., Tanaka, Y., Ishii, T., George, M.D., Klionsky, D.J., Ohsumi, M., and Ohsumi, Y. (1998). A protein conjugation system essential for autophagy. Nature 395, 395-398.
72. Mooradian, A.D. (1996). Drug therapy of non-insulin-dependent diabetes mellitus in the elderly. Drugs 51, 931-941.
73. Murtola, T.J., Tammela, T.L., Lahtela, J., and Auvinen, A. (2008). Antidiabetic medication and prostate cancer risk: a population-based case-control study. Am. J. Epidemiol. 168, 925-931.
74. Nagata, D., Mogi, M., and Walsh, K. (2003). AMP-activated protein kinase (AMPK) signaling in endothelial cells is essential for angiogenesis in response to hypoxic stress. J. Biol. Chem. 278, 31000-31006.
75. Niehr, F., Von Euw, E., Attar, N. et al. (2011). Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations. J. Transl. Med. 9, 76.
76. Novosyadlyy, R., and Leroith, D. (2010). Hyperinsulinemia and type 2 diabetes: impact on cancer. Cell Cycle 9, 1449-1450.
77. Obara, K., and Ohsumi, Y. (2008). Dynamics and function of PtdIns(3)P in autophagy. Autophagy 4, 952-954.
78. Ohanna, M., Cheli, Y., Bonet, C. et al. (2013). Secretome from senescent melanoma engages the STAT3 pathway to favor reprogramming of naive melanoma towards a tumor-initiating cell phenotype. Oncotarget 4, 2212-2224.
79. Okoshi, R., Ozaki, T., Yamamoto, H., Ando, K., Koida, N., Ono, S., Koda, T., Kamijo, T., Nakagawara, A., and Kizaki, H. (2008). Activation of AMP-activated protein kinase induces p53-dependent apoptotic cell death in response to energetic stress. J. Biol. Chem. 283, 3979-3987.
80. Oliveras-Ferraros, C., Vazquez-Martin, A., and Menendez, J.A. (2009). Genome-wide inhibitory impact of the AMPK activator metformin on [kinesins, tubulins, histones, auroras and polo-like kinases] M-phase cell cycle genes in human breast cancer cells. Cell Cycle 8, 1633-1636.
81. Owen, M.R., Doran, E., and Halestrap, A.P. (2000). Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem. J. 348(Pt 3), 607-614.
82. Pandolfi, P.P. (2004). Aberrant mRNA translation in cancer pathogenesis: an old concept revisited comes finally of age. Oncogene 23, 3134-3137.
83. Pattingre, S., and Levine, B. (2006). Bcl-2 inhibition of autophagy: a new route to cancer? Cancer Res. 66, 2885-2888.
84. Pawelczyk, L., Spaczynski, R.Z., Banaszewska, B., and Duleba, A.J. (2004). Metformin therapy increases insulin-like growth factor binding protein-1 in hyperinsulinemic women with polycystic ovary syndrome. Eur. J. Obstet. Gynecol. Reprod. Biol. 113, 209-213.
85. Petti, C., Vegetti, C., Molla, A., Bersani, I., Cleris, L., Mustard, K.J., Formelli, F., Hardie, G.D., Sensi, M., and Anichini, A. (2012). AMPK activators inhibit the proliferation of human melanomas bearing the activated MAPK pathway. Melanoma Res. 22, 341-350.
86. Phoenix, K.N., Vumbaca, F., and Claffey, K.P. (2009). Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERalpha negative MDA-MB-435 breast cancer model. Breast Cancer Res. Treat. 113, 101-111.
87. Radoshevich, L., Murrow, L., Chen, N., Fernandez, E., Roy, S., Fung, C., and Debnath, J. (2010). ATG12 conjugation to ATG3 regulates mitochondrial homeostasis and cell death. Cell 142, 590-600.
88. Rattan, R., Giri, S., Hartmann, L.C., and Shridhar, V. (2011). Metformin attenuates ovarian cancer cell growth in an AMP-kinase dispensable manner. J. Cell Mol. Med. 15, 166-178.
89. Roesch, A., Vultur, A., Bogeski, I. et al. (2013). Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells. Cancer Cell 23, 811-825.
90. Saeedi, R., Parsons, H.L., Wambolt, R.B., Paulson, K., Sharma, V., Dyck, J.R., Brownsey, R.W., and Allard, M.F. (2008). Metabolic actions of metformin in the heart can occur by AMPK-independent mechanisms. Am. J. Physiol. Heart Circ. Physiol. 294, H2497-H2506.
91. Sakamoto, K., Mccarthy, A., Smith, D., Green, K.A., Grahame Hardie, D., Ashworth, A., and Alessi, D.R. (2005). Deficiency of LKB1 in skeletal muscle prevents AMPK activation and glucose uptake during contraction. EMBO J. 24, 1810-1820.
92. Sancak, Y., and Sabatini, D.M. (2009). Rag proteins regulate amino-acid-induced mTORC1 signalling. Biochem. Soc. Trans. 37, 289-290.
93. Sarbassov, D.D., Ali, S.M., and Sabatini, D.M. (2005). Growing roles for the mTOR pathway. Curr. Opin. Cell Biol. 17, 596-603.
94. Schneider, M.B., Matsuzaki, H., Haorah, J., Ulrich, A., Standop, J., Ding, X.Z., Adrian, T.E., and Pour, P.M. (2001). Prevention of pancreatic cancer induction in hamsters by metformin. Gastroenterology 120, 1263-1270.
95. Segal, E.D., Yasmeen, A., Beauchamp, M.C., Rosenblatt, J., Pollak, M., and Gotlieb, W.H. (2011). Relevance of the OCT1 transporter to the antineoplastic effect of biguanides. Biochem. Biophys. Res. Commun. 414, 694-699.
96. Shackelford, D.B., and Shaw, R.J. (2009). The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat. Rev. Cancer 9, 563-575.
97. Shaw, R.J., Kosmatka, M., Bardeesy, N., Hurley, R.L., Witters, L.A., Depinho, R.A., and Cantley, L.C. (2004). The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc. Natl Acad. Sci. USA 101, 3329-3335.
98. Shu, Y., Sheardown, S.A., Brown, C. et al. (2007). Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J. Clin. Invest. 117, 1422-1431.
99. Smalley, K.S. (2010). PLX-4032, a small-molecule B-Raf inhibitor for the potential treatment of malignant melanoma. Curr. Opin. Investig. Drugs 11, 699-706.
100. Stades, A.M., Heikens, J.T., Erkelens, D.W., Holleman, F., and Hoekstra, J.B. (2004). Metformin and lactic acidosis: cause or coincidence? A review of case reports. J. Intern. Med. 255, 179-187.
101. Swinnen, J.V., Beckers, A., Brusselmans, K. et al. (2005). Mimicry of a cellular low energy status blocks tumor cell anabolism and suppresses the malignant phenotype. Cancer Res. 65, 2441-2448.
102. Tasdemir, E., Maiuri, M.C., Tajeddine, N., Vitale, I., Criollo, A., Vicencio, J.M., Hickman, J.A., Geneste, O., and Kroemer, G. (2007). Cell cycle-dependent induction of autophagy, mitophagy and reticulophagy. Cell Cycle 6, 2263-2267.
103. Tomic, T., Botton, T., Cerezo, M. et al. (2011). Metformin inhibits melanoma development through autophagy and apoptosis mechanisms. Cell Death Dis. 2, e199.
104. Ueno, M., Carvalheira, J.B., Tambascia, R.C., Bezerra, R.M., Amaral, M.E., Carneiro, E.M., Folli, F., Franchini, K.G., and Saad, M.J. (2005). Regulation of insulin signalling by hyperinsulinaemia: role of IRS-1/2 serine phosphorylation and the mTOR/p70 S6K pathway. Diabetologia 48, 506-518.
105. Wang, L.W., Li, Z.S., Zou, D.W., Jin, Z.D., Gao, J., and Xu, G.M. (2008). Metformin induces apoptosis of pancreatic cancer cells. World J. Gastroenterol. 14, 7192-7198.
106. Warburg, O. (1956). On the origin of cancer cells. Science 123, 309-314.
107. Woodard, J., and Platanias, L.C. (2010). AMP-activated kinase (AMPK)-generated signals in malignant melanoma cell growth and survival. Biochem. Biophys. Res. Commun. 398, 135-139.
108. Xie, Z., and Klionsky, D.J. (2007). Autophagosome formation: core machinery and adaptations. Nat. Cell Biol. 9, 1102-1109.
109. Xie, Z., Dong, Y., Scholz, R., Neumann, D., and Zou, M.H. (2008). Phosphorylation of LKB1 at serine 428 by protein kinase C-zeta is required for metformin-enhanced activation of the AMP-activated protein kinase in endothelial cells. Circulation 117, 952-962.
110. Yee, D. (2006). Targeting insulin-like growth factor pathways. Br. J. Cancer 94, 465-468.
111. Yuan, P., Ito, K., Perez-Lorenzo, R., Del Guzzo, C., Lee, J.H., Shen, C.H., Bosenberg, M.W., Mcmahon, M., Cantley, L.C., and Zheng, B. (2013). Phenformin enhances the therapeutic benefit of BRAFV600E inhibition in melanoma. Proc. Natl Acad. Sci. USA 110, 18226-18231.
112. Zabierowski, S.E., and Herlyn, M. (2008). Melanoma stem cells: the dark seed of melanoma. J. Clin. Oncol. 26, 2890-2894.
113. Zakikhani, M., Dowling, R., Fantus, I.G., Sonenberg, N., and Pollak, M. (2006). Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res. 66, 10269-10273.
114. Zeiser, R., Schnitzler, M., Andrlova, H., Hellige, T., and Meiss, F. (2012). Immunotherapy for malignant melanoma. Curr. Stem Cell Res. Ther. 7, 217-228.
115. Zhou, G., Myers, R., Li, Y. et al. (2001). Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 108, 1167-1174.
116. Zhuang, Y., and Miskimins, W.K. (2008). Cell cycle arrest in Metformin treated breast cancer cells involves activation of AMPK, downregulation of cyclin D1, and requires p27Kip1 or p21Cip1. J. Mol. Signal. 3, 18.